AstraZeneca drug does not extend lives of breast cancer patients – Financial Times

by
  1. AstraZeneca drug does not extend lives of breast cancer patientsFinancial Times
  2. AstraZeneca, Daiichi suffer new setback with mixed results from breast cancer drugsBloomberg
  3. AstraZeneca, competitor to Daiichi’s Trodelvy, fails to improve overall survival in breast cancer trialFierce biotechnology
  4. T-DXd Outperforms Physicians’ Choice Treatment in QOL for HR+/HER2-Low/Ultralow MBCwww.oncnursingnews.com/
  5. Datopotamab Deruxtecan Overall Survival Results Reported in Patients with Metastatic HR-Positive, HER2-Low or -Negative Breast Cancer in TROPION-Breast01 Phase 3 StudyYahoo Finance

Leave a Comment